ArticleMolecular biology reports2025
Altered miR-203a and miR-3622b-5p expressions in multiple sclerosis: novel correlations with apoptotic gene expression profiles.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDefective apoptosis of autoreactive immune cells contributes to multiple sclerosis (MS) pathogenesis. Survivin (BIRC5), an anti-apoptotic protein, and interleukin-4 (IL-4), а cytokine with dual immunomodulatory roles, are potential key players. This study investigates the expression of BIRC5, IL-4, and three apoptosis-associated miRNAs (miR-203a, miR-3622b-5p, miR-198) in MS, focusing on their regulatory interplay. METHODS AND
resultsWhole blood RNA from 28 relapsing-remitting MS patients and 27 healthy controls was analyzed via qRT-PCR. BIRC5 and IL-4 expression were significantly elevated in MS patients (p = 0.008; p = 0.012). miR-203a (p = 0.005) and miR-3622b-5p (p = 0.003) showed marked upregulation, while miR-198 remained unchanged. Bioinformatics prediction (TargetScan/ miRDB) identified conserved binding sites for miR-203a and miR-3622b-5p in the 3'UTR of BIRC5 and IL-4, supported by strong correlations (BIRC5-miR-203a: r = 0.65, p = 0.002; IL-4-miR-3622b-5p: r = 0.58, p = 0.007). Gene ontology analysis linked these molecules to apoptotic resistance (GO:0043066) and Th2 signaling (KEGG:04630).
conclusionsThis study reveals a dysregulated BIRC5/IL-4/miRNA axis in MS, where miR-203a and miR-3622b-5p potentially enhance survivin and IL-4 expression, promoting immune cell survival. These findings highlight miRNA-mediated post-transcriptional regulation as a novel therapeutic target for restoring apoptotic balance in MS.
Indexed as
Identifiers
41065895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.